Principles on authorship, sources, conflicts of interest, corrections and retractions
MakingPharmaIndustry Working Papers is committed to editorial transparency, responsible publication practices and the clear disclosure of authorship, sources and potential conflicts of interest.
The following principles apply to papers published within the series.
Authorship
Authors are responsible for the originality, accuracy and integrity of their contributions.
All listed authors should have made a substantial contribution to the conception, preparation, drafting or revision of the paper and should approve the final version before publication.
Any person or organization that contributed to the preparation of the paper but does not meet the criteria for authorship may be acknowledged where appropriate.
Sources and references
Papers must provide appropriate references to the data, reports, scientific literature, regulatory documents, institutional sources and other materials used in the preparation of the work.
Authors are encouraged to rely on primary sources whenever possible, including official documents, peer-reviewed literature, regulatory guidance, institutional reports and authoritative datasets.
Conflicts of interest
Authors are required to disclose any financial, professional, institutional or personal relationships that could be perceived as influencing the content of the paper.
Potential conflicts of interest may include, but are not limited to:
- employment, consultancy or advisory roles;
- grants, sponsorships or financial support;
- commercial relationships;
- institutional affiliations;
- participation in projects directly related to the topic of the paper.
Disclosures may be published together with the paper.
Originality and plagiarism
Submissions should be original and should not include plagiarized material.
Authors are responsible for ensuring that all quoted, paraphrased or adapted content is properly attributed.
If a paper is based on previous work, reports, presentations or conference materials, this should be clearly indicated.
Use of generative artificial intelligence
When generative artificial intelligence tools are used in the preparation of a manuscript, authors should disclose their use where relevant.
Authors remain fully responsible for the accuracy, originality, integrity and final content of the submitted paper.
Generative AI tools should not be listed as authors.
Corrections
If factual errors are identified after publication, the editorial office may publish a correction or update the paper.
When corrections are substantial, the nature and date of the correction should be clearly indicated.
Retractions
In cases involving serious factual errors, plagiarism, undisclosed conflicts of interest, unreliable data or other significant breaches of publication ethics, the editorial office may retract the paper.
Retraction notices should remain publicly available and should clearly explain the reason for the retraction.
Editorial responsibility
The MakingPharmaIndustry editorial office is responsible for assessing submitted papers, coordinating the editorial process and ensuring that published contributions are consistent with the scope and ethical principles of the series.
The publisher may decline, correct, update or retract content when necessary to preserve the integrity of the series.
